- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Inflammatory bowel disease (IBD) |
|---|
|
| Oncological conditions |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Hypoglycaemia (especially with low BMI or children <6 years).
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Purine analogues | ||
|---|---|---|
| L01BB06 | ||
| L01BB05 | ||
| L01BB07 | ||
| L01BB03 | ||
| Pyrimidine analogues | ||
|---|---|---|
| L01BC01 | ||
| L01BC52 | ||
| L01BC05 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Turner D, et al., Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN Evidence-Based Consensus Guidelines, JPGN, 2012, 55(3), 340-61
- GlaxoSmithKline BV, SPC Puri-Nethol (RVG 00589) 13-2-2019, www.cbg-meb.nl
- Nova, SmPC Xaluprine 20mg/ml Suspension zum Einnehmen (EU/1/11/727/001), 07/2017
- MEDICE, SmPC Mercaptopurin 10mg Tabletten (64742.00.00), 10/2017
- Aspen, SmPC Puri-Nethol 50mg Tabletten (6102083.00.00), 09/2017
- Informatorium Medicamentorum., (Interacties), Geraadpleegd 16 aug 2018
- Nova, SmPC Xaluprine 20mg/ml Suspension zum Einnehmen (EU/1/11/727/001), 07/2017
- Wine E. et al., Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation, JPGN, 2025, 81(3), 765-815
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
